Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Sep;26(9):937-43.
doi: 10.1002/gps.2630. Epub 2010 Dec 28.

A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

D P Devanand  1 , Gregory H Pelton, Karine Cunqueiro, Harold A Sackeim, Karen Marder
Affiliations
Randomized Controlled Trial

A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

D P Devanand et al. Int J Geriatr Psychiatry. 2011 Sep.

Abstract

Objective: In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation.

Methods: In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of haloperidol (0.5-5 mg daily) were randomized to a 24-week, double-blind pilot trial of discontinuation on placebo versus continuation haloperidol. Phase A response criteria were minimum 50% reduction in three target symptoms, and improvement on the Clinical Global Impression-Change (CGI-C) score for psychosis/agitation. Phase B relapse criteria required 50% worsening in target symptoms and on the CGI-C. α = 0.1 was the significance criterion in this pilot study.

Results: Of 44 patients, 22 patients responded in Phase A. The sum score of target symptoms, and Brief Psychiatric Rating Scale (BPRS) psychosis and hostile suspiciousness factor scores, decreased in Phase A (p's < 0.001). Extrapyramidal signs increased in Phase A (p < 0.01). Of 22 responders, 21 patients entered Phase B, and 20 had at least one follow-up visit. Four of 10 patients (40%) on continuation haloperidol relapsed compared to eight of 10 patients on placebo (80%, χ(2) = 3.3, p = 0.07). In survival analyses, time to relapse was shorter on placebo than haloperidol (χ(2) = 4.1, p = 0.04).

Conclusions: Haloperidol open treatment was efficacious, and relapse was greater on placebo than with haloperidol continuation. In patients with AD who have psychosis or agitation and respond to antipsychotic medication, the increased risk of relapse after discontinuation needs to be weighed against the side effects associated with continuing the medication.

PubMed Disclaimer

Figures

Figure 1
Figure 1
STUDY FLOW SHEET.
Figure 2
Figure 2
CONSORT diagram of recruitment and patient flow through the study.
Figure 3
Figure 3
See this image and copyright information in PMC

References

    1. Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psych. 2004;65:114–119. - PubMed
    1. Ballard C, Margallo Lana M, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing to take or discontinued from treatment with neuroleptics (the DARTAD trial) PLoS Med. 2008;5:e76. - PMC - PubMed
    1. Ballard C, Brown R, Fossey J, Douglas S, Bradley P, Hancock J, James IA, Juszczak E, Bentham P, Burns A, Lindesay J, Jacoby R, O’Brien J, Bullock R, Johnson T, Holmes C, Howard R. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (The CALM-AD trial) Am J Geriatr Psychiatry. 2009a;17(9):726–33. - PubMed
    1. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009b;8(2):151–7. - PubMed
    1. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797–811. - PubMed

Publication types